Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Prenetics Global Limited is a genomics and precision medicine company that operates at the intersection of genetic testing, molecular diagnostics, and personalized health. The company provides DNA testing and diagnostic solutions for disease risk assessment, oncology, and infectious diseases, serving consumers, healthcare providers, and enterprise partners. Prenetics operates primarily within the biotechnology, healthcare diagnostics, and genomics industries, generating revenue through genetic testing kits, laboratory services, and enterprise contracts.
The company’s core business lines include consumer genetic testing through CircleDNA, oncology-focused molecular diagnostics through ACT Genomics, and infectious disease testing, which became a significant revenue driver during the COVID‑19 pandemic. Prenetics positions itself as a clinically focused genomics company with an emphasis on high-depth whole genome sequencing and regulated laboratory infrastructure. Founded in 2014, the company expanded rapidly in Asia before listing on Nasdaq in 2022 through a business combination, evolving from a consumer DNA testing startup into a broader precision medicine platform.
Business Operations
Prenetics operates through multiple business units that collectively generate revenue from testing services, diagnostics, and health insights. Its primary operating segments include CircleDNA, which provides direct-to-consumer genetic testing covering health, wellness, and ancestry, and ACT Genomics, which delivers comprehensive genomic profiling for cancer patients to support precision oncology treatment decisions. The company also operates certified clinical laboratories that support molecular diagnostics and infectious disease testing.
Operations span both consumer and clinical channels, with laboratory infrastructure in Asia-Pacific and North America. Prenetics controls proprietary sequencing workflows, bioinformatics platforms, and accredited laboratory assets that enable compliance with medical and regulatory standards. The company has historically partnered with governments, healthcare systems, and corporate clients for large-scale testing programs and maintains subsidiaries that support laboratory operations, data analytics, and regional commercialization.
Strategic Position & Investments
Prenetics’ strategic direction centers on expanding precision medicine capabilities, scaling oncology diagnostics, and leveraging genomic data to support preventive healthcare. The company has invested significantly in laboratory infrastructure, clinical validation, and regulatory compliance to differentiate its offerings from consumer-only genetic testing competitors. A key strategic asset is ACT Genomics, which positions Prenetics within the fast-growing precision oncology market.
The company has pursued selective acquisitions and investments to enhance sequencing depth, clinical relevance, and geographic reach, while divesting or de-emphasizing lower-margin pandemic-related testing as demand normalized. Emerging focus areas include early cancer detection, liquid biopsy technologies, and integration of genomic data into clinical decision-making, supported by ongoing investment in bioinformatics and laboratory automation.
Geographic Footprint
Prenetics maintains a global operational footprint with headquarters in Hong Kong and significant operations across Asia-Pacific, North America, and Europe. The company has established a strong market presence in Hong Kong, Mainland China, and Southeast Asia, where it initially scaled consumer genetic testing and government-backed diagnostics.
Internationally, Prenetics has expanded into the United States and the United Kingdom, supporting oncology diagnostics, enterprise testing, and research collaborations. Its geographic diversification allows access to multiple healthcare systems, regulatory environments, and population datasets, supporting both commercial growth and clinical development initiatives.
Leadership & Governance
Prenetics was founded by Danny Yeung, who has guided the company’s evolution from a consumer genomics startup to a publicly listed precision medicine company. Leadership emphasizes scientific rigor, regulatory compliance, and long-term value creation through clinically actionable genomics rather than lifestyle-only testing.
Key executives include:
- Danny Yeung – Co‑Founder and Chief Executive Officer
- David Mudd – Chief Financial Officer
- Prof. Lo Yuk‑ming – Scientific Co‑Founder and Advisor
- Dr. Jonathan Ng – Chief Medical Officer
- Chris Lacey – Chief Operating Officer
The leadership team combines expertise in genomics research, clinical medicine, finance, and global operations, supporting the company’s strategy of integrating science-driven innovation with scalable commercial execution.